Posts by Sandra Ansanay-Alex
A CHF multimillion investment for Mimix Biotherapeutics
Mimix Biotherapeutics in Biel (Bern) secures significant investment to translate and commercialize a new treatment technique for human tissue regeneration. The strategic investors are supporting MimiX’s vision to transform the lives of millions of patients suffering from chronic wounds. The investment will accelerate the development and commercialization of FastSkin®, a revolutionary treatment that…
Read MoreBioArk Monthey: a 3rd building dedicated to life sciences and biotechnologies
BioArk is on a roll! The Monthey-based technology site, which is celebrating its 20th anniversary this year, inaugurated its third building on Friday 13 October 2023. And it is almost already full! This new showcase, which houses companies specialising in life sciences and biotechnology, is already virtually full. It is proof that The…
Read MoreBioAlps Association Privacy Policy
BioAlps Association’s Privacy Statement: The purpose of this Privacy Policy is to inform you of the procedures regarding the collection, use and disclosure of information on the BioAlps website, including any mobile versions or related mobile applications, collectively called BioAlps Association Sites. 1. About BioAlps Association Founded in 2003, BioAlps Association empowers the…
Read MoreGeneral Terms and Conditions
General Terms and Conditions – BioAlps Association Use of material on this website Material and database on this website may be reproduced, made available or revised for derivative works on other websites or databases without express permission which can be obtained from contact@bioalps.org. You may link to the relevant page on this website…
Read MoreLonza further expands in Visps thanks to a new partnership
A new agreement with an undisclosed global biopharmaceutical partner will quadruple current dedicated bioconjugation capacity by adding two new production units for the commercial supply of Antibody-Drug Conjugates (ADC) at Lonza’s Ibex® Dedicate biopark in Visp (CH). 180 jobs will be created. The announcement of Moderna’s departure does not hinder Lonza’s expansion! This…
Read MoreNovostia starts clinical trials of its new heart valve in Lituania
Novostia has received the green light from the Lithuanian State Health Care Accreditation Agency under the Ministry of Health to launch the First-in-Human implantations (FIH) of its aortic heart valve prosthesis: the TRIFLO. These implants are scheduled to begin in December 2023, at Vilnius University Hospital Santaros Klinikos, under the supervision of Professor Kęstutis…
Read MoreMedicrops acquires Swiss Alpinopharma
A strategic move to enhance digital patient care in the booming European cannabis market. MediCrops Holding AG (‘MediCrops’), based in Schwyz and at Biopôle in Lausanne, has acquired Berlin-based company Swiss Alpinopharma GmbH (‘Swiss Alpinopharma’), a disruptive market leader in the field of medical cannabis and owner of telemedicine platform Enmedify. Swiss Alpinopharma…
Read MoreCovid-19 Research: Aerium Therapeutics begins development of three in-licensed antibodies
Aerium Therapeutics, a company based in Lausanne and Boston, focuses on the development of antiviral therapeutics for COVID-19 and emerging viral threats. Aerium Therapeutics announced that it has licensed and begun development of three monoclonal antibodies (mAbs) with broad and potent activity against the predominant variants of SARS-CoV-2 (the virus that causes COVID-19),…
Read MoreCancer Research: HES-SO Valais-Wallis and Debiopharm sign a partnership
The Life Technologies Institute of the Haute École d’Ingénierie has signed a new five-year collaboration agreement with Debiopharm Research & Manufacturing S.A. in Martigny. Funded to the extent of CHF 1.1 million by Debiopharm, with the possibility of a further CHF 1 million bonus, this joint research project aims to revolutionise the preparation of conjugates…
Read MoreCancer Research: ISREC Foundation and EPFL announce the creation of the Paternot Chair
The chair will be held by Professor Nicolas Thomä. The ISREC Foundation is contributing to the funding of the Chair with a donation of CHF 7.5 million. The Chair is named in memory of Yves Paternot, a tireless patron of the arts and President of the ISREC Foundation who passed away in 2016, and whose…
Read More